{
  "id": "neurosyphilis",
  "title": "Neurosyphilis",
  "version": "1.1",
  "icd10": [
    "** A52.2 (Asymptomatic neurosyphilis)",
    "A52.3 (Neurosyphilis",
    "unspecified)",
    "A52.13 (Late syphilitic meningitis)",
    "A52.14 (Late syphilitic encephalitis)"
  ],
  "scope": "** Evaluation and management of neurosyphilis including early neurosyphilis (meningeal, meningovascular), late neurosyphilis (general paresis, tabes dorsalis), and ocular/otic syphilis. Includes diagnosis, treatment with IV penicillin G, management of Jarisch-Herxheimer reaction, penicillin desensitization for allergic patients, and post-treatment monitoring with serial CSF analysis. Excludes primary/secondary syphilis without CNS involvement, congenital syphilis, and HIV-specific antiretroviral management.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs": [
        {
          "item": "RPR (serum) (CPT 86592)",
          "rationale": "Non-treponemal screening test; quantitative titer used for treatment response monitoring; sensitivity ~70-80% in late syphilis (prozone effect possible)",
          "target": "Reactive with titer (document titer for follow-up comparison)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "VDRL (serum) (CPT 86592)",
          "rationale": "Alternative non-treponemal screening; quantitative titer; VDRL is the only validated non-treponemal test for CSF",
          "target": "Reactive with titer",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "FTA-ABS (serum) (CPT 86780)",
          "rationale": "Treponemal confirmatory test; remains positive for life after infection; high sensitivity and specificity",
          "target": "Reactive (confirms treponemal exposure)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "TP-PA (serum) (CPT 86780)",
          "rationale": "Treponemal confirmatory test; alternative to FTA-ABS; high specificity",
          "target": "Reactive",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Treponemal IgG/IgM EIA or CIA (serum)",
          "rationale": "Many labs now use reverse screening algorithm (treponemal test first); automated, high throughput",
          "target": "Reactive",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "HIV 1/2 antigen/antibody (4th generation) (CPT 87389)",
          "rationale": "High co-infection rate (syphilis-HIV co-infection in 25-70% in some populations); HIV affects neurosyphilis presentation, treatment response, and monitoring schedule",
          "target": "Document result; if positive, obtain CD4 and viral load",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CBC with differential (CPT 85025)",
          "rationale": "Baseline; infection markers; lymphocytosis may be present",
          "target": "Normal or mild lymphocytosis",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CMP (BMP + LFTs) (CPT 80053)",
          "rationale": "Renal function for penicillin dosing; hepatic function; electrolytes",
          "target": "Normal; document baseline Cr",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "ESR (CPT 85651)",
          "rationale": "Elevated in active syphilis; non-specific inflammatory marker",
          "target": "Often elevated",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "CRP (CPT 86140)",
          "rationale": "Inflammatory marker; baseline",
          "target": "May be mildly elevated",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        }
      ],
      "Extended Workup (Second-line)": [
        {
          "item": "CD4 count and HIV viral load (CPT 86360)",
          "rationale": "If HIV positive; CD4 <350 increases risk of neurosyphilis; affects monitoring frequency",
          "target": "Document baseline; CD4 <350 = higher risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Hepatitis B surface antigen, surface antibody, core antibody (CPT 87340)",
          "rationale": "Co-infection screening (shared risk factors); hepatitis may complicate treatment",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Hepatitis C antibody (CPT 86803)",
          "rationale": "Co-infection screening",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Gonorrhea/Chlamydia NAAT (CPT 87591)",
          "rationale": "STI co-infection screening; shared risk factors",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Coagulation panel (PT/INR, aPTT) (CPT 85610+85730)",
          "rationale": "Before lumbar puncture; coagulopathy workup",
          "target": "Normal",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Blood glucose (paired with CSF) (CPT 82947)",
          "rationale": "CSF:serum glucose ratio interpretation",
          "target": "Document paired with LP",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Serum B12 level (CPT 82607)",
          "rationale": "Subacute combined degeneration in differential (posterior column dysfunction like tabes dorsalis)",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "TSH (CPT 84443)",
          "rationale": "Thyroid dysfunction in differential of cognitive decline",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "ANA, dsDNA (CPT 86235)",
          "rationale": "SLE meningitis/cerebritis in differential; biological false-positive RPR seen in SLE",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Rare/Specialized (Refractory or Atypical)": [
        {
          "item": "Treponemal PCR (CSF) (CPT 87798)",
          "rationale": "Limited availability; lower sensitivity than serology; may be useful in early infection before antibody response",
          "target": "Negative (positive confirms T. pallidum DNA)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Antiphospholipid antibodies (CPT 86146)",
          "rationale": "Syphilis can cause biological false-positive; meningovascular syphilis with stroke differential includes antiphospholipid syndrome",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Autoimmune encephalitis panel (serum + CSF) (CPT 86255)",
          "rationale": "General paresis may mimic autoimmune encephalitis (psychiatric symptoms, cognitive decline)",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "Paraneoplastic panel (serum) (CPT 86255)",
          "rationale": "Rapidly progressive dementia differential",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "ACE level (serum) (CPT 82164)",
          "rationale": "Neurosarcoidosis in differential (cranial neuropathies, meningitis)",
          "target": "Normal",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Whipple PCR (CSF or tissue)",
          "rationale": "Whipple disease in differential (dementia, ophthalmoplegia, ataxia)",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        }
      ],
      "Lumbar Puncture": [
        {
          "item": "Opening pressure",
          "rationale": "Elevated in syphilitic meningitis",
          "target": "Normal or mildly elevated (10-20 cm H2O); elevated in acute meningitis",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cell count with differential (tubes 1 and 4) (CPT 89051)",
          "rationale": "CSF pleocytosis is the hallmark of active neurosyphilis; lymphocytic predominant; most sensitive CSF marker",
          "target": "WBC >5 cells/uL (lymphocyte predominant); typically 10-400 cells/uL; elevated WBC is the most sensitive indicator of active CNS infection",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Protein (CPT 84157)",
          "rationale": "Elevated in neurosyphilis (45-200 mg/dL)",
          "target": "Elevated (>45 mg/dL); typically 50-200 mg/dL",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Glucose with paired serum glucose (CPT 82945)",
          "rationale": "May be mildly decreased; helps distinguish from other causes of meningitis",
          "target": "Normal or mildly low (>60% serum glucose ratio); markedly low glucose suggests bacterial or TB meningitis",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "CSF VDRL (CPT 86592)",
          "rationale": "GOLD STANDARD for neurosyphilis diagnosis; highly SPECIFIC (99%) but sensitivity only 30-70%. A REACTIVE CSF VDRL confirms neurosyphilis. A NON-REACTIVE CSF VDRL does NOT exclude neurosyphilis",
          "target": "Reactive = diagnostic of neurosyphilis. Non-reactive does NOT rule out neurosyphilis",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "CSF FTA-ABS (CPT 86780)",
          "rationale": "More SENSITIVE than CSF VDRL (>95%) but LESS SPECIFIC (false positives from blood contamination). A NEGATIVE CSF FTA-ABS essentially rules out neurosyphilis. Used mainly to EXCLUDE the diagnosis",
          "target": "Non-reactive = neurosyphilis unlikely. Reactive = possible neurosyphilis (but not confirmatory due to lower specificity)",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "CSF RPR",
          "rationale": "NOT validated for CSF; some labs offer it but CSF VDRL is the standard non-treponemal test for CSF",
          "target": "CSF VDRL preferred; CSF RPR has uncertain performance characteristics",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Gram stain and bacterial culture (CPT 87205+87070)",
          "rationale": "Exclude bacterial meningitis if acute presentation",
          "target": "No organisms",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "BioFire FilmArray ME Panel (CPT 87483)",
          "rationale": "Rapid multiplex PCR to exclude bacterial/viral meningitis if acute presentation",
          "target": "Negative (no bacterial or viral pathogen identified)",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Oligoclonal bands, IgG index (CPT 83916)",
          "rationale": "Intrathecal antibody production; elevated in neurosyphilis; also elevated in MS (differential)",
          "target": "Often positive (intrathecal IgG synthesis); not specific to syphilis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "AFB smear and culture (CPT 87116)",
          "rationale": "TB meningitis in differential (chronic lymphocytic meningitis)",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Cytology (CPT 88104)",
          "rationale": "Leptomeningeal malignancy in differential",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-"
        },
        {
          "item": "Cryptococcal antigen (CSF) (CPT 87327)",
          "rationale": "HIV co-infection; chronic meningitis differential",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "-"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "item": "MRI brain with and without contrast (CPT 70553)",
          "timing": "Within 24-48h; STAT if acute stroke symptoms or altered consciousness",
          "target": "Meningovascular: cerebral infarction (especially MCA territory in young patient), meningeal enhancement, gummatous lesions. General paresis: frontotemporal atrophy, mesial temporal T2 hyperintensity. Tabes dorsalis: spinal cord atrophy. May be NORMAL in early/asymptomatic neurosyphilis",
          "contraindications": "Pacemaker, metallic implants",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CT head without contrast (CPT 70450)",
          "timing": "Immediate in ED if acute presentation (stroke, altered consciousness, seizure)",
          "target": "Infarction (meningovascular), hydrocephalus, calcified gumma; may be normal",
          "contraindications": "Pregnancy (relative)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "ECG (12-lead) (CPT 93000)",
          "timing": "On admission; before penicillin infusion",
          "target": "Baseline; syphilitic aortitis (conduction abnormalities); QTc for concurrent medications",
          "contraindications": "None",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        }
      ],
      "Extended": [
        {
          "item": "MRI spine (cervical/thoracic) with contrast (CPT 72156)",
          "timing": "If myelopathy symptoms (tabes dorsalis, syphilitic myelitis)",
          "target": "Spinal cord atrophy (tabes dorsalis: posterior columns), meningeal enhancement, myelitis signal change",
          "contraindications": "Same as MRI",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "MRA head and neck (CPT 70544+70547)",
          "timing": "If meningovascular syphilis with stroke suspected",
          "target": "Arteritis; vessel wall enhancement; stenosis (medium and large vessels); aneurysm",
          "contraindications": "Same as MRI",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "CT angiography head and neck (CPT 70496)",
          "timing": "If MRA not available and stroke suspected",
          "target": "Same as MRA",
          "contraindications": "Contrast allergy; renal impairment",
          "ED": "STAT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Echocardiogram (TTE) (CPT 93306)",
          "timing": "If cardiovascular syphilis suspected (aortitis); concurrent evaluation",
          "target": "Aortic regurgitation; ascending aortic aneurysm; aortitis",
          "contraindications": "None significant",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Chest X-ray (CPT 71046)",
          "timing": "Admission; cardiovascular syphilis screening",
          "target": "Ascending aortic calcification (eggshell pattern); aortic dilatation",
          "contraindications": "None significant",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "Vessel wall MRI (high-resolution)",
          "timing": "If meningovascular syphilis with negative standard MRA",
          "target": "Concentric vessel wall enhancement (vasculitis pattern); distinguishes from atherosclerotic disease",
          "contraindications": "Same as MRI",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "FDG-PET brain (CPT 78816)",
          "timing": "Atypical cognitive decline; general paresis with unclear diagnosis",
          "target": "Frontotemporal hypometabolism (general paresis pattern)",
          "contraindications": "Pregnancy",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "EEG (routine or continuous) (CPT 95816)",
          "timing": "If seizures or altered mental status",
          "target": "Focal slowing; generalized slowing (general paresis); epileptiform discharges",
          "contraindications": "None significant",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "CT/MRI aorta with contrast",
          "timing": "If cardiovascular syphilis suspected (aortitis, aneurysm)",
          "target": "Ascending aortic aneurysm; aortitis",
          "contraindications": "Contrast allergy; renal impairment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Nerve conduction studies / EMG (CPT 95907+95861)",
          "timing": "Peripheral neuropathy evaluation; tabes dorsalis differential",
          "target": "Sensory neuropathy pattern; dorsal root ganglionopathy",
          "contraindications": "Anticoagulation (relative for EMG)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent": [
        {
          "item": "Penicillin G (aqueous crystalline) (CPT 96365)",
          "route": "IV",
          "indication": "First-line treatment for ALL forms of neurosyphilis (meningeal, meningovascular, general paresis, tabes dorsalis, ocular syphilis, otic syphilis)",
          "dosing": {
            "doseOptions": [
              {
                "text": "3-4 million units q4h",
                "orderSentence": "Penicillin G (aqueous crystalline) (CPT 96365) 3-4 million units q4h IV"
              }
            ],
            "route": "IV",
            "instructions": "18-24 million units/day IV, given as 3-4 million units IV q4h continuously for 10-14 days. Infuse each dose over 30-60 min. Alternative: continuous IV infusion 18-24 million units/day. Duration: minimum 10-14 days",
            "orderSentence": "Penicillin G (aqueous crystalline) (CPT 96365) 3-4 million units q4h IV"
          },
          "contraindications": "Penicillin anaphylaxis (perform desensitization -- see below); dose adjust for severe renal impairment (CrCl <10: 2-3 million units q4h)",
          "monitoring": "Renal function (BUN, Cr) daily; serum potassium (high-dose penicillin contains potassium); CBC; monitor for Jarisch-Herxheimer reaction in first 24h; monitor for seizures at very high doses",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "IV normal saline (hydration)",
          "route": "IV",
          "indication": "Maintain hydration during IV penicillin therapy; prevent volume depletion",
          "dosing": {
            "doseOptions": [
              {
                "text": "75-125 mL/h",
                "orderSentence": "IV normal saline (hydration) 75-125 mL/h IV"
              }
            ],
            "route": "IV",
            "instructions": "75-125 mL/h IV maintenance; bolus 500-1000 mL if dehydrated",
            "orderSentence": "IV normal saline (hydration) 75-125 mL/h IV"
          },
          "contraindications": "Volume overload, CHF",
          "monitoring": "I/O; electrolytes daily",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Acetaminophen (Jarisch-Herxheimer prophylaxis/treatment)",
          "route": "PO/IV",
          "indication": "Prophylaxis and treatment of Jarisch-Herxheimer reaction (fever, rigors, headache, myalgia occurring 2-8h after first penicillin dose; occurs in up to 50% of neurosyphilis patients)",
          "dosing": {
            "doseOptions": [
              {
                "text": "650-1000 mg q6h",
                "orderSentence": "Acetaminophen (Jarisch-Herxheimer prophylaxis/treatment) 650-1000 mg q6h PO"
              }
            ],
            "route": "PO",
            "instructions": "650-1000 mg PO/IV q6h for first 24-48h of treatment; premedicate before first penicillin dose",
            "orderSentence": "Acetaminophen (Jarisch-Herxheimer prophylaxis/treatment) 650-1000 mg q6h PO"
          },
          "contraindications": "Severe hepatic disease",
          "monitoring": "Temperature; LFTs",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Methylprednisolone (severe Jarisch-Herxheimer prevention)",
          "route": "IV",
          "indication": "Prevention of severe Jarisch-Herxheimer reaction in patients at high risk (high RPR titer, HIV co-infection, ocular/otic syphilis with risk of permanent vision/hearing loss, meningovascular syphilis with stroke risk)",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg daily",
                "orderSentence": "Methylprednisolone 500 mg IV daily"
              },
              {
                "text": "1000 mg daily",
                "orderSentence": "Methylprednisolone 1000 mg IV daily"
              },
              {
                "text": "1 g daily x3-5 days",
                "orderSentence": "Methylprednisolone 1 g IV daily x3-5 days"
              }
            ],
            "route": "IV",
            "instructions": "60-125 mg IV 30 min before first penicillin dose to attenuate Jarisch-Herxheimer reaction",
            "orderSentence": "Methylprednisolone 500 mg IV daily"
          },
          "contraindications": "Active untreated infection (relative); uncontrolled diabetes",
          "monitoring": "Glucose; blood pressure",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Probenecid (with IM penicillin alternative)",
          "route": "PO",
          "indication": "Used ONLY with procaine penicillin G IM regimen (alternative to IV penicillin when IV access impossible); blocks renal excretion of penicillin to maintain treponemicidal CSF levels",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg QID",
                "orderSentence": "Probenecid (with IM penicillin alternative) 500 mg QID PO"
              }
            ],
            "route": "PO",
            "instructions": "500 mg PO QID for 10-14 days (must be given with each IM penicillin dose); ensure adequate hydration",
            "orderSentence": "Probenecid (with IM penicillin alternative) 500 mg QID PO"
          },
          "contraindications": "Uric acid nephrolithiasis; blood dyscrasias; sulfonamide allergy",
          "monitoring": "Uric acid; renal function; ensure compliance (QID dosing)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Procaine penicillin G IM (alternative ONLY if IV not feasible)",
          "route": "IM",
          "indication": "Alternative to IV penicillin G ONLY when IV access is impossible. MUST be combined with probenecid. CDC considers this acceptable but less preferred than IV",
          "dosing": {
            "doseOptions": [
              {
                "text": "2.4 million units daily",
                "orderSentence": "Procaine penicillin G IM (alternative ONLY if IV not feasible) 2.4 million units daily IM"
              }
            ],
            "route": "IM",
            "instructions": "2.4 million units IM daily for 10-14 days PLUS probenecid 500 mg PO QID. This regimen REQUIRES strict compliance with probenecid; any missed doses compromise CSF levels",
            "orderSentence": "Procaine penicillin G IM (alternative ONLY if IV not feasible) 2.4 million units daily IM"
          },
          "contraindications": "Procaine allergy; injection site concerns",
          "monitoring": "Injection sites; compliance with probenecid; clinical response",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Symptomatic Treatments": [
        {
          "item": "Gabapentin",
          "route": "PO",
          "indication": "Neuropathic pain (lightning pains of tabes dorsalis; lancinating pain)",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg TID",
                "orderSentence": "Gabapentin 100 mg PO TID"
              },
              {
                "text": "300 mg TID",
                "orderSentence": "Gabapentin 300 mg PO TID"
              },
              {
                "text": "600 mg TID",
                "orderSentence": "Gabapentin 600 mg PO TID"
              },
              {
                "text": "900 mg TID",
                "orderSentence": "Gabapentin 900 mg PO TID"
              },
              {
                "text": "1200 mg TID",
                "orderSentence": "Gabapentin 1200 mg PO TID"
              }
            ],
            "route": "PO",
            "instructions": "Start 300 mg qHS; titrate by 300 mg q1-3d to 300-900 mg TID; max 3600 mg/day",
            "orderSentence": "Gabapentin 100 mg PO TID"
          },
          "contraindications": "Severe renal impairment (dose adjust: CrCl <60)",
          "monitoring": "Sedation; dizziness; edema; renal function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Pregabalin",
          "route": "PO",
          "indication": "Neuropathic pain (tabes dorsalis; alternative to gabapentin)",
          "dosing": {
            "doseOptions": [
              {
                "text": "50 mg TID",
                "orderSentence": "Pregabalin 50 mg PO TID"
              },
              {
                "text": "75 mg BID",
                "orderSentence": "Pregabalin 75 mg PO BID"
              },
              {
                "text": "100 mg TID",
                "orderSentence": "Pregabalin 100 mg PO TID"
              },
              {
                "text": "150 mg BID",
                "orderSentence": "Pregabalin 150 mg PO BID"
              },
              {
                "text": "200 mg BID",
                "orderSentence": "Pregabalin 200 mg PO BID"
              },
              {
                "text": "300 mg BID",
                "orderSentence": "Pregabalin 300 mg PO BID"
              }
            ],
            "route": "PO",
            "instructions": "Start 75 mg BID; may increase to 150-300 mg BID q1wk; max 600 mg/day",
            "orderSentence": "Pregabalin 50 mg PO TID"
          },
          "contraindications": "Severe renal impairment (dose adjust); angioedema history",
          "monitoring": "Sedation; weight gain; edema; renal function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Carbamazepine",
          "route": "PO",
          "indication": "Lancinating/lightning pain of tabes dorsalis (particularly effective for paroxysmal neuropathic pain)",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg BID",
                "orderSentence": "Carbamazepine 100 mg PO BID"
              },
              {
                "text": "200 mg BID",
                "orderSentence": "Carbamazepine 200 mg PO BID"
              },
              {
                "text": "400 mg BID",
                "orderSentence": "Carbamazepine 400 mg PO BID"
              },
              {
                "text": "600 mg BID",
                "orderSentence": "Carbamazepine 600 mg PO BID"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg BID; titrate by 200 mg/day q1wk; target 400-800 mg/day; max 1200 mg/day",
            "orderSentence": "Carbamazepine 100 mg PO BID"
          },
          "contraindications": "AV block; history of bone marrow suppression; concurrent MAOIs; HLA-B*1502 positive (Asian descent -- screen before starting)",
          "monitoring": "CBC with differential q2wk x 2 months then q3 months; LFTs; sodium (SIADH); drug level (target 4-12 ug/mL)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Duloxetine",
          "route": "PO",
          "indication": "Neuropathic pain (tabes dorsalis); concurrent depression",
          "dosing": {
            "doseOptions": [
              {
                "text": "30 mg daily",
                "orderSentence": "Duloxetine 30 mg PO daily"
              },
              {
                "text": "60 mg daily",
                "orderSentence": "Duloxetine 60 mg PO daily"
              },
              {
                "text": "90 mg daily",
                "orderSentence": "Duloxetine 90 mg PO daily"
              },
              {
                "text": "120 mg daily",
                "orderSentence": "Duloxetine 120 mg PO daily"
              }
            ],
            "route": "PO",
            "instructions": "Start 30 mg daily x 1 wk; increase to 60 mg daily; max 120 mg/day",
            "orderSentence": "Duloxetine 30 mg PO daily"
          },
          "contraindications": "Severe hepatic impairment; concurrent MAOIs; uncontrolled narrow-angle glaucoma",
          "monitoring": "LFTs; blood pressure; serotonin syndrome symptoms",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Levetiracetam",
          "route": "IV/PO",
          "indication": "Seizures (neurosyphilis-related seizures; meningovascular with cortical involvement)",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg BID",
                "orderSentence": "Levetiracetam 250 mg IV BID"
              },
              {
                "text": "500 mg BID",
                "orderSentence": "Levetiracetam 500 mg IV BID"
              },
              {
                "text": "750 mg BID",
                "orderSentence": "Levetiracetam 750 mg IV BID"
              },
              {
                "text": "1000 mg BID",
                "orderSentence": "Levetiracetam 1000 mg IV BID"
              },
              {
                "text": "1500 mg BID",
                "orderSentence": "Levetiracetam 1500 mg IV BID"
              }
            ],
            "route": "IV",
            "instructions": "1000-1500 mg IV load; then 500-1000 mg IV/PO BID; max 3000 mg/day",
            "orderSentence": "Levetiracetam 250 mg IV BID"
          },
          "contraindications": "Severe renal impairment (dose adjust)",
          "monitoring": "Renal function; mood/behavioral changes",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Lorazepam",
          "route": "IV",
          "indication": "Active seizure rescue",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5 mg TID",
                "orderSentence": "Lorazepam 0.5 mg IV TID"
              },
              {
                "text": "1 mg TID",
                "orderSentence": "Lorazepam 1 mg IV TID"
              },
              {
                "text": "2 mg TID",
                "orderSentence": "Lorazepam 2 mg IV TID"
              }
            ],
            "route": "IV",
            "instructions": "0.1 mg/kg IV (max 4 mg); may repeat x1 in 5 min",
            "orderSentence": "Lorazepam 0.5 mg IV TID"
          },
          "contraindications": "Respiratory depression; severe hepatic failure",
          "monitoring": "RR, SpO2; airway equipment ready",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Sertraline",
          "route": "PO",
          "indication": "Depression (common with general paresis and chronic neurosyphilis)",
          "dosing": {
            "doseOptions": [
              {
                "text": "50 mg",
                "orderSentence": "Sertraline 50 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 50 mg daily; increase by 50 mg q2-4wk; max 200 mg/day",
            "orderSentence": "Sertraline 50 mg PO"
          },
          "contraindications": "Concurrent MAOIs; QT prolongation",
          "monitoring": "Suicidality monitoring (first 4 weeks); serotonin syndrome",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Quetiapine",
          "route": "PO",
          "indication": "Psychotic symptoms (general paresis with psychosis, paranoid delusions, grandiosity)",
          "dosing": {
            "doseOptions": [
              {
                "text": "12.5 mg QHS",
                "orderSentence": "Quetiapine 12.5 mg PO QHS"
              },
              {
                "text": "25 mg QHS",
                "orderSentence": "Quetiapine 25 mg PO QHS"
              },
              {
                "text": "50 mg QHS",
                "orderSentence": "Quetiapine 50 mg PO QHS"
              },
              {
                "text": "100 mg QHS",
                "orderSentence": "Quetiapine 100 mg PO QHS"
              }
            ],
            "route": "PO",
            "instructions": "Start 25 mg BID; titrate slowly to 50-100 mg BID; target 150-300 mg/day for psychosis",
            "orderSentence": "Quetiapine 12.5 mg PO QHS"
          },
          "contraindications": "QT prolongation; dementia-related psychosis (black box)",
          "monitoring": "Metabolic panel q3 months; fasting glucose; lipids; QTc; tardive dyskinesia monitoring",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Haloperidol",
          "route": "IV/IM",
          "indication": "Acute agitation with psychosis (general paresis with severe agitation)",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.5 mg BID",
                "orderSentence": "Haloperidol 0.5 mg IV BID"
              },
              {
                "text": "1 mg BID",
                "orderSentence": "Haloperidol 1 mg IV BID"
              },
              {
                "text": "2 mg BID",
                "orderSentence": "Haloperidol 2 mg IV BID"
              },
              {
                "text": "5 mg q4h PRN",
                "orderSentence": "Haloperidol 5 mg IV q4h PRN"
              }
            ],
            "route": "IV",
            "instructions": "2-5 mg IV/IM q4-6h PRN; max 20 mg/day",
            "orderSentence": "Haloperidol 0.5 mg IV BID"
          },
          "contraindications": "QT prolongation; Parkinson disease; dementia (black box)",
          "monitoring": "QTc monitoring; EPS; vital signs",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Metoclopramide",
          "route": "PO",
          "indication": "Gastroparesis (visceral autonomic neuropathy in tabes dorsalis)",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg TID",
                "orderSentence": "Metoclopramide 5 mg PO TID"
              },
              {
                "text": "10 mg TID",
                "orderSentence": "Metoclopramide 10 mg PO TID"
              },
              {
                "text": "10 mg QID",
                "orderSentence": "Metoclopramide 10 mg PO QID"
              }
            ],
            "route": "PO",
            "instructions": "10 mg PO 30 min before meals and at bedtime; max 40 mg/day; limit to 12 weeks",
            "orderSentence": "Metoclopramide 5 mg PO TID"
          },
          "contraindications": "Parkinson disease; tardive dyskinesia; bowel obstruction",
          "monitoring": "Tardive dyskinesia; EPS (limit duration)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Oxybutynin",
          "route": "PO",
          "indication": "Bladder dysfunction (neurogenic bladder in tabes dorsalis; urgency/incontinence)",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg BID",
                "orderSentence": "Oxybutynin 5 mg PO BID"
              },
              {
                "text": "5 mg TID",
                "orderSentence": "Oxybutynin 5 mg PO TID"
              },
              {
                "text": "10 mg daily XL",
                "orderSentence": "Oxybutynin 10 mg PO daily XL"
              },
              {
                "text": "15 mg daily XL",
                "orderSentence": "Oxybutynin 15 mg PO daily XL"
              }
            ],
            "route": "PO",
            "instructions": "Start 5 mg BID; may increase to 5 mg TID; max 15 mg/day",
            "orderSentence": "Oxybutynin 5 mg PO BID"
          },
          "contraindications": "Urinary retention; uncontrolled narrow-angle glaucoma; GI obstruction",
          "monitoring": "Post-void residual; anticholinergic effects (cognition in elderly)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Second-line/Refractory": [
        {
          "item": "Ceftriaxone IV (alternative to penicillin G)",
          "route": "IV",
          "indication": "Alternative for neurosyphilis when penicillin desensitization is not feasible; CDC-recommended alternative. Evidence supports adequate CSF penetration and treponemicidal activity",
          "dosing": {
            "doseOptions": [
              {
                "text": "2 g daily",
                "orderSentence": "Ceftriaxone IV (alternative to penicillin G) 2 g daily IV"
              }
            ],
            "route": "IV",
            "instructions": "2 g IV daily for 10-14 days. Some experts recommend 14 days. Limited clinical trial data but supported by observational studies and CDC guidelines",
            "orderSentence": "Ceftriaxone IV (alternative to penicillin G) 2 g daily IV"
          },
          "contraindications": "Cephalosporin anaphylaxis; severe penicillin allergy with cephalosporin cross-reactivity (low risk, ~1-2%)",
          "monitoring": "Renal function; CBC; LFTs; biliary sludge with prolonged use",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Penicillin desensitization protocol (for penicillin-allergic patients)",
          "route": "PO then IV",
          "indication": "Penicillin allergy with no acceptable alternative; allows safe IV penicillin G administration. Desensitization takes 4-6 hours and must be done in monitored setting (ICU or equivalent)",
          "dosing": {
            "doseOptions": [
              {
                "text": "See Appendix A",
                "orderSentence": "Penicillin desensitization protocol (for penicillin-allergic patients) See Appendix A PO then IV"
              }
            ],
            "route": "PO then IV",
            "instructions": "Oral desensitization protocol over 4-6h (see Appendix A); begin IV penicillin G immediately after desensitization complete; patient must remain on continuous penicillin (no gaps >8h or desensitization is lost)",
            "orderSentence": "Penicillin desensitization protocol (for penicillin-allergic patients) See Appendix A PO then IV"
          },
          "contraindications": "Anaphylaxis to penicillin (proceed with extreme caution in ICU); unstable cardiac/respiratory status",
          "monitoring": "Continuous cardiac monitoring; SpO2; BP q15min during protocol; epinephrine at bedside; IV access x2; crash cart available",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Doxycycline (third-line alternative)",
          "route": "PO",
          "indication": "Third-line alternative ONLY when both IV penicillin and ceftriaxone are contraindicated; limited evidence for neurosyphilis; better studied for early syphilis",
          "dosing": {
            "doseOptions": [
              {
                "text": "200 mg BID",
                "orderSentence": "Doxycycline (third-line alternative) 200 mg BID PO"
              }
            ],
            "route": "PO",
            "instructions": "200 mg PO BID for 28 days. Some experts recommend 30 days. LOWER confidence in CNS penetration; use only if no other option. Close CSF monitoring mandatory",
            "orderSentence": "Doxycycline (third-line alternative) 200 mg BID PO"
          },
          "contraindications": "Pregnancy; children <8 years; concurrent retinoids",
          "monitoring": "LFTs; sun protection counseling; GI tolerance; photosensitivity",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Corticosteroids (adjunctive for ocular/otic syphilis)",
          "route": "PO/IV",
          "indication": "Adjunctive anti-inflammatory therapy for ocular syphilis (uveitis, optic neuritis, retinal vasculitis) or otic syphilis to prevent permanent vision/hearing loss; used in addition to IV penicillin, not as standalone",
          "dosing": {
            "doseOptions": [
              {
                "text": "1 mg/kg daily",
                "orderSentence": "Corticosteroids (adjunctive for ocular/otic syphilis) 1 mg/kg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Prednisone 1 mg/kg/day PO (max 60 mg) with IV penicillin; taper over 2-4 weeks based on ophthalmology/ENT guidance; or IV methylprednisolone 250 mg q6h x 3 days then oral taper for severe cases",
            "orderSentence": "Corticosteroids (adjunctive for ocular/otic syphilis) 1 mg/kg daily PO"
          },
          "contraindications": "Uncontrolled diabetes; active GI bleed; psychosis (relative)",
          "monitoring": "Glucose; BP; GI prophylaxis; ophtho/ENT follow-up",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Infectious disease consultation for treatment optimization, duration guidance, penicillin desensitization planning, and HIV co-management",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Neurology consultation for diagnosis confirmation, CSF interpretation, differentiation of neurosyphilis subtypes, and management of neurologic complications",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Ophthalmology STAT evaluation for ALL patients with ocular symptoms (vision loss, floaters, photophobia) as ocular syphilis can cause permanent blindness without prompt treatment",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Audiology evaluation for ALL patients with hearing loss or tinnitus (otic syphilis) for baseline audiometry and monitoring",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "ENT consultation for otic syphilis evaluation and management of sensorineural hearing loss",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Psychiatry consultation for behavioral/psychiatric symptoms in general paresis (psychosis, personality change, cognitive decline, depression)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Allergy/Immunology consultation for penicillin desensitization if patient reports penicillin allergy",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Neuropsychology for formal cognitive testing in suspected general paresis (dementia evaluation, treatment response monitoring)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical therapy for gait training, balance rehabilitation, and fall prevention in tabes dorsalis (sensory ataxia, proprioceptive loss)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Occupational therapy for ADL assessment and adaptive strategies given proprioceptive and fine motor deficits",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Social work for STI partner notification coordination, housing stability, substance use resources, and discharge planning",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Public health department notification (syphilis is a reportable disease in all US states)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Sexual health/STI clinic referral for partner notification, ongoing STI screening, and prevention counseling",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Return to ED if: new vision loss, worsening headache, new weakness, seizure, confusion, hearing loss, or high fever after starting treatment (Jarisch-Herxheimer reaction may worsen in first 24h)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Complete the FULL course of IV penicillin (10-14 days); do NOT stop treatment early even if symptoms improve, as incomplete treatment leads to relapse and progressive CNS damage",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Expect possible fever, chills, headache, and muscle aches within 2-12 hours of first penicillin dose (Jarisch-Herxheimer reaction); this is a normal inflammatory response and NOT an allergic reaction; notify nursing staff but do NOT stop antibiotics",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Abstain from sexual contact until treatment is complete and RPR titers decline to confirm cure; use condoms consistently after treatment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "All sexual partners from the past 90 days (primary), 6 months (secondary), or 1 year (latent) must be notified and tested for syphilis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Follow-up blood tests (RPR titers) required at 3, 6, 12, and 24 months after treatment to confirm cure; failure of titers to decline by 4-fold at 6-12 months may indicate treatment failure",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Follow-up lumbar puncture required at 6 months (and possibly 3, 12, and 24 months) after treatment to confirm CSF normalization",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Report any new neurologic symptoms (vision changes, hearing changes, numbness, balance problems, cognitive changes) between follow-up visits as they may indicate treatment failure or reinfection",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "If HIV positive: ensure adherence to antiretroviral therapy as HIV co-infection increases risk of treatment failure and neurosyphilis relapse",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Driving restrictions if cognitive impairment, seizures, or significant visual deficit until cleared by neurology",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Safer sex practices: consistent condom use reduces but does not eliminate syphilis transmission risk; regular STI screening for sexually active individuals",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Alcohol cessation as alcohol worsens cognitive impairment and neuropathy, and complicates medication adherence and follow-up",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "HIV pre-exposure prophylaxis (PrEP) discussion for patients at ongoing risk who are HIV-negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Fall prevention measures including assistive devices, home safety evaluation, and nightlight use for patients with sensory ataxia (tabes dorsalis), as proprioceptive loss worsens in darkness",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cognitive rehabilitation strategies including memory aids, structured routines, and supervised medication management for patients with general paresis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Regular exercise appropriate to functional level for cardiovascular health and prevention of deconditioning",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Smoking cessation to reduce vascular risk (especially important in meningovascular syphilis with stroke risk)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "HIV-associated neurocognitive disorder (HAND)",
      "features": "Progressive cognitive decline in HIV; may coexist with neurosyphilis; no CSF pleocytosis unless opportunistic infection",
      "tests": "HIV viral load (CSF and serum); CD4 count; syphilis serologies negative; MRI: diffuse atrophy"
    },
    {
      "diagnosis": "Tuberculous meningitis",
      "features": "Subacute/chronic meningitis; basilar predominance; cranial neuropathies; CSF: lymphocytic, very low glucose, very high protein",
      "tests": "AFB culture; TB PCR (GeneXpert); ADA; chest X-ray (miliary pattern); PPD/IGRA"
    },
    {
      "diagnosis": "Cryptococcal meningitis",
      "features": "HIV/immunocompromised; chronic headache; elevated opening pressure; minimal pleocytosis",
      "tests": "CSF cryptococcal antigen; India ink; fungal culture; serum CrAg"
    },
    {
      "diagnosis": "CNS vasculitis (primary or secondary)",
      "features": "Multifocal strokes in young patient; headache; cognitive decline; CSF pleocytosis",
      "tests": "Brain biopsy (gold standard); vessel wall MRI; CTA/MRA; ESR/CRP; ANA; ANCA; syphilis serologies to exclude"
    },
    {
      "diagnosis": "Multiple sclerosis",
      "features": "Relapsing-remitting neurologic deficits; optic neuritis; myelopathy; white matter lesions",
      "tests": "MRI (periventricular/juxtacortical lesions; Dawson fingers); CSF oligoclonal bands; syphilis screen (should be done in all MS workups)"
    },
    {
      "diagnosis": "Autoimmune encephalitis (anti-NMDAR, LGI1)",
      "features": "Psychiatric symptoms; seizures; movement disorders; subacute onset",
      "tests": "Autoimmune encephalitis antibody panel (serum + CSF); MRI; EEG"
    },
    {
      "diagnosis": "Neurosarcoidosis",
      "features": "Cranial neuropathies (especially CN VII); chronic meningitis; granulomatous inflammation",
      "tests": "Chest CT (hilar adenopathy); serum/CSF ACE; biopsy; CSF lymphocytic; syphilis serologies negative"
    },
    {
      "diagnosis": "CNS lymphoma",
      "features": "Progressive cognitive decline in immunocompromised; periventricular enhancing lesion",
      "tests": "MRI with contrast; CSF cytology; EBV PCR (CSF); stereotactic biopsy"
    },
    {
      "diagnosis": "Normal pressure hydrocephalus",
      "features": "Triad: gait apraxia, urinary incontinence, dementia; ventriculomegaly out of proportion to atrophy",
      "tests": "Large volume LP (improvement after 30-40 mL removal); MRI (ventriculomegaly, DESH); gait assessment pre/post LP"
    },
    {
      "diagnosis": "Vitamin B12 deficiency myelopathy",
      "features": "Posterior column dysfunction (like tabes dorsalis); peripheral neuropathy; megaloblastic anemia",
      "tests": "Serum B12; methylmalonic acid; homocysteine; MRI spine (dorsal column signal)"
    },
    {
      "diagnosis": "Lyme neuroborreliosis",
      "features": "Cranial neuropathies (CN VII); radiculopathy; meningitis; endemic area exposure; erythema migrans history",
      "tests": "Lyme serologies (ELISA + Western blot); CSF Lyme antibody index; CSF pleocytosis"
    },
    {
      "diagnosis": "Whipple disease",
      "features": "Oculomasticatory myorhythmia (pathognomonic); dementia; GI symptoms; arthritis",
      "tests": "Whipple PCR (CSF/tissue); small bowel biopsy; PAS-positive macrophages"
    },
    {
      "diagnosis": "Behcet disease",
      "features": "Oral/genital ulcers; uveitis; CNS involvement; young adults; Mediterranean/Asian descent",
      "tests": "Clinical criteria (recurrent ulcers); pathergy test; HLA-B51; CSF pleocytosis"
    },
    {
      "diagnosis": "Chronic meningitis (other causes)",
      "features": "Persistent headache, cranial neuropathies, CSF pleocytosis >4 weeks",
      "tests": "Full chronic meningitis workup: syphilis, TB, fungal, Lyme, sarcoid, malignancy"
    }
  ],
  "evidence": [
    {
      "recommendation": "IV penicillin G 18-24 million units/day x 10-14 days for neurosyphilis",
      "evidenceLevel": "Class I, Level A",
      "source": "[CDC STI Treatment Guidelines 2021](https://pubmed.ncbi.nlm.nih.gov/34292926/); [Workowski et al. MMWR 2021](https://pubmed.ncbi.nlm.nih.gov/34292926/)"
    },
    {
      "recommendation": "CSF VDRL is the standard diagnostic test for neurosyphilis (highly specific but insensitive)",
      "evidenceLevel": "Class I, Level B",
      "source": "[Marra et al. CID 2004](https://pubmed.ncbi.nlm.nih.gov/15796090/)"
    },
    {
      "recommendation": "CSF FTA-ABS has high negative predictive value (negative result essentially excludes neurosyphilis)",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Marra et al. JID 2004](https://pubmed.ncbi.nlm.nih.gov/14745693/)"
    },
    {
      "recommendation": "CSF pleocytosis (WBC >5) is the most sensitive marker of active neurosyphilis",
      "evidenceLevel": "Class I, Level B",
      "source": "[Marra et al. Clin Infect Dis 2008](https://pubmed.ncbi.nlm.nih.gov/18715153/)"
    },
    {
      "recommendation": "Ceftriaxone 2g IV daily x 10-14 days as alternative to penicillin",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Marra et al. CID 2000](https://pubmed.ncbi.nlm.nih.gov/11749352/); CDC STI Guidelines 2021"
    },
    {
      "recommendation": "Serial CSF monitoring at 6-month intervals post-treatment",
      "evidenceLevel": "Class I, Level B",
      "source": "[Marra et al. Neurology 2004](https://pubmed.ncbi.nlm.nih.gov/15249615/)"
    },
    {
      "recommendation": "HIV co-infection increases risk of neurosyphilis and treatment failure",
      "evidenceLevel": "Class I, Level B",
      "source": "[Ghanem et al. CID 2008](https://pubmed.ncbi.nlm.nih.gov/19308585/)"
    },
    {
      "recommendation": "LP recommended for all HIV-positive patients with syphilis (especially CD4 <350 or RPR >=1:32)",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Ghanem et al. STD 2009](https://pubmed.ncbi.nlm.nih.gov/20180366/); CDC STI Guidelines 2021"
    },
    {
      "recommendation": "Ocular syphilis requires neurosyphilis treatment (IV penicillin) regardless of CSF findings",
      "evidenceLevel": "Class I, Level B",
      "source": "[Oliver et al. STD 2016](https://pubmed.ncbi.nlm.nih.gov/28702511/); CDC Clinical Advisory 2015"
    },
    {
      "recommendation": "Otic syphilis requires neurosyphilis treatment (IV penicillin) regardless of CSF findings",
      "evidenceLevel": "Class I, Level B",
      "source": "CDC STI Treatment Guidelines 2021"
    },
    {
      "recommendation": "Jarisch-Herxheimer reaction occurs in up to 50% of neurosyphilis patients",
      "evidenceLevel": "Class IIa, Level B",
      "source": "Expert consensus; [Belum et al. Am J Med 2013](https://pubmed.ncbi.nlm.nih.gov/23996476/)"
    },
    {
      "recommendation": "Penicillin desensitization is safe and effective for penicillin-allergic patients requiring treatment",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Wendel et al. NEJM 1985](https://pubmed.ncbi.nlm.nih.gov/3921835/)"
    },
    {
      "recommendation": "Four-fold decline in serum RPR by 6-12 months defines adequate treatment response",
      "evidenceLevel": "Class I, Level B",
      "source": "CDC STI Treatment Guidelines 2021"
    },
    {
      "recommendation": "CSF WBC should normalize within 6 months of successful treatment",
      "evidenceLevel": "Class I, Level B",
      "source": "[Marra et al. Neurology 2004](https://pubmed.ncbi.nlm.nih.gov/15249615/)"
    },
    {
      "recommendation": "Retreatment indicated if CSF WBC has not declined at 6 months",
      "evidenceLevel": "Class IIa, Level B",
      "source": "CDC STI Guidelines 2021; [Marra et al. CID 2004](https://pubmed.ncbi.nlm.nih.gov/15796090/)"
    },
    {
      "recommendation": "Doxycycline 200 mg BID x 28 days as third-line alternative (limited evidence)",
      "evidenceLevel": "Class IIb, Level C",
      "source": "Expert consensus; limited data for CNS penetration"
    },
    {
      "recommendation": "All patients with syphilis should be tested for HIV",
      "evidenceLevel": "Class I, Level A",
      "source": "CDC STI Treatment Guidelines 2021; WHO Guidelines"
    }
  ],
  "monitoring": [
    {
      "item": "Neurologic exam (mental status, cranial nerves, motor, sensory, gait)",
      "frequency": "q4-8h inpatient; each outpatient visit",
      "action": "If declining: reassess treatment; repeat imaging; repeat LP",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Temperature (Jarisch-Herxheimer monitoring)",
      "frequency": "q2h for first 24h of treatment, then q4h",
      "action": "Acetaminophen; IV fluids; if severe: corticosteroids; do NOT stop penicillin",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "-",
      "ICU": "STAT"
    },
    {
      "item": "Serum RPR/VDRL titer",
      "frequency": "Baseline, then at 3, 6, 12, and 24 months post-treatment",
      "action": "If no 4-fold decline by 6-12 months: consider treatment failure; repeat LP; retreat",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "CSF analysis (cell count, protein, VDRL) -- follow-up LP",
      "frequency": "At 6 months post-treatment; repeat q6 months until normal; some experts also check at 3, 12, 24 months",
      "action": "If CSF WBC not declining at 6 months: retreat with IV penicillin 10-14 days; if HIV+, check at 3 months",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Serum potassium",
      "frequency": "Daily during IV penicillin (high-dose penicillin contains 1.7 mEq K+ per million units)",
      "action": "If hyperkalemic: reduce potassium intake; cardiac monitoring; if hypokalemic: supplement",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "-",
      "ICU": "STAT"
    },
    {
      "item": "Renal function (BUN, Cr)",
      "frequency": "Daily during IV penicillin; each outpatient visit",
      "action": "Dose adjust penicillin if renal impairment develops",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Visual acuity and fundoscopic exam",
      "frequency": "Each visit if ocular syphilis",
      "action": "Urgent ophthalmology re-evaluation if worsening; reassess corticosteroid dose",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Audiometry",
      "frequency": "Baseline, then at 1, 3, 6, 12 months if otic syphilis",
      "action": "ENT re-evaluation; consider corticosteroid adjustment",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "HIV viral load and CD4 (if co-infected)",
      "frequency": "At syphilis diagnosis, then per HIV monitoring schedule",
      "action": "If unsuppressed HIV: higher risk of neurosyphilis treatment failure; optimize ART",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Seizure monitoring",
      "frequency": "Clinical observation inpatient; EEG if seizures",
      "action": "Adjust AED; if status epilepticus: follow SE protocol",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Blood pressure",
      "frequency": "q4h inpatient; each outpatient visit",
      "action": "If hypertensive crisis during JH reaction: treat symptomatically",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    }
  ],
  "disposition": [
    {
      "disposition": "Discharge home (with OPAT -- outpatient parenteral antibiotic therapy)",
      "criteria": "Neurologically stable; no active seizures; mild symptoms; reliable outpatient IV access (PICC line); home infusion services arranged; reliable patient with follow-up arranged; no significant comorbidities requiring monitoring"
    },
    {
      "disposition": "Admit to floor",
      "criteria": "Confirmed or highly suspected neurosyphilis requiring IV penicillin initiation; need for Jarisch-Herxheimer monitoring; moderate neurologic deficits; seizure monitoring; ocular or otic syphilis requiring urgent subspecialty evaluation"
    },
    {
      "disposition": "Admit to ICU",
      "criteria": "Severe meningovascular syphilis with acute stroke; status epilepticus; acute vision loss requiring emergent management; penicillin desensitization protocol (requires continuous monitoring); severe Jarisch-Herxheimer reaction with hemodynamic instability; altered consciousness (GCS <13)"
    },
    {
      "disposition": "Transfer to higher level",
      "criteria": "Need for penicillin desensitization not available at current facility; need for neuro-ophthalmology not available; need for neurosurgery if hydrocephalus or mass lesion"
    },
    {
      "disposition": "Outpatient management",
      "criteria": "Asymptomatic neurosyphilis with mild CSF abnormalities; stable patient who can receive IV penicillin via OPAT or complete procaine penicillin IM + probenecid regimen; established diagnosis with completed inpatient treatment transitioning to monitoring"
    }
  ]
}
